Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
For second-line chemotherapy for metastatic gastric cancer, single-agent irinotecan is the
standard treatment. Anthracyclines are active but lack well designed investigations. The
combination of epirubicin, fluorouracil and cisplatin (or oxaliplatin) are widely used in
Europe. However, traditional anthracyclines are more cardiotoxic; and (Pegliposomal
Doxorubicin) PLD, as a new liposome dosage form of doxorubicin, has better cardiac safety.
Therefore, we designed this phase II trial with PLD and 5-Fu to compare irinotecan
monotherapy in the second-line treatment.